Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 8/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | SGK1 | O00141 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29780238 | 1.00 | CYP11B1 (0.45) | CYP11B1CYP11B2HAO1HTR2ASLC6A4 | |
| SCHEMBL23478383 | 0.85 | PTGS1 (0.46) | CYP11B1CYP11B2EPAS1PPARGPTGS2 | |
| SCHEMBL29780207 | 0.85 | PTGS1 (0.46) | CYP11B1CYP11B2EPAS1PPARGPTGS2 | |
| SCHEMBL29780201 | 0.81 | EPAS1 (0.55) | EPAS1 | |
| SCHEMBL23478137 | 0.81 | EPAS1 (0.55) | EPAS1 | |
| SCHEMBL23461418 | 0.77 | EPAS1 (0.50) | EPAS1 | |
| SCHEMBL29780182 | 0.77 | EPAS1 (0.55) | EPAS1 | |
| SCHEMBL23461077 | 0.77 | EPAS1 (0.55) | EPAS1 | |
| SCHEMBL29780229 | 0.77 | EPAS1 (0.50) | EPAS1 | |
| SCHEMBL23461093 | 0.75 | BRD4 (0.52) | EPAS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024438-A1 | INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2021113436-A1 | INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024438-A1 | INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | CYP11B1 859/4885CYP11B2 358/4885HAO1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.